Beer, T. M. et al. Randomized, double-blind, section III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic sufferers with metastatic chemotherapy-naive castration-resistant prostate most cancers. J. Clin. Oncol. 35, 40–47 (2017).
Kwon, E. D. et al. Ipilimumab versus placebo after radiotherapy in sufferers with metastatic castration-resistant prostate most cancers that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, section 3 trial. Lancet Oncol. 15, 700–712 (2014).
Fong, P. C. et al. Pembrolizumab plus enzalutamide in abiraterone-pretreated sufferers with metastatic castrate resistant prostate most cancers: cohort C of the section 1b/2 KEYNOTE-365 research. J. Clin. Oncol. 37, suppl:abstr 5010 (2019)
Sharma, P. et al. Nivolumab plus ipilimumab for metastatic castration-resistant prostate most cancers: preliminary evaluation of sufferers within the CheckMate 650 trial. Most cancers Cell. 38, 489–499 (2020).
Antonarakis, E. S. et al. Pembrolizumab for treatment-refractory metastatic castration-resistant prostate most cancers: multicohort, open-label section II KEYNOTE-199 research. J. Clin. Oncol. 38, 395–405 (2020).
Conforti, F. et al. Most cancers immunotherapy efficacy and sufferers’ intercourse: a scientific evaluate and meta-analysis. Lancet Oncol. 19, 737–746 (2018).
Small, E. J. et al. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in sufferers with hormone-refractory prostate most cancers. Clin. Most cancers Res. 13, 1810–1815 (2007).
Kissick, H. T. et al. Androgens alter T-cell immunity by inhibiting T-helper 1 differentiation. Proc. Natl Acad. Sci. USA 111, 9887–9892 (2014).
Benten, W. P. et al. Purposeful testosterone receptors in plasma membranes of T cells. FASEB J. 13, 123–133 (1999).
Liva, S. M. & Voskuhl, R. R. Testosterone acts immediately on CD4+ T lymphocytes to extend IL-10 manufacturing. J. Immunol. 167, 2060–2067 (2001).
Walecki, M. et al. Androgen receptor modulates Foxp3 expression in CD4+CD25+Foxp3+ regulatory T-cells. Mol. Biol. Cell 26, 2845–2857 (2015).
Ayers, M. et al. IFN-gamma-related mRNA profile predicts medical response to PD-1 blockade. J. Clin. Make investments. 127, 2930–2940 (2017).
Prat, A. et al. Immune-related gene expression profiling after PD-1 blockade in non-small cell lung carcinoma, head and neck squamous cell carcinoma, and melanoma. Most cancers Res. 77, 3540–3550 (2017).
Riaz, N. et al. Tumor and microenvironment evolution throughout immunotherapy with nivolumab. Cell 171, 934–949.e916 (2017).
Graff, J. N. et al. Early proof of anti-PD-1 exercise in enzalutamide-resistant prostate most cancers. Oncotarget 7, 52810–52817 (2016).
Graff, J. N. et al. A section II single-arm research of pembrolizumab with enzalutamide in males with metastatic castration-resistant prostate most cancers progressing on enzalutamide alone. J. Immunother. Most cancers. 8, e000642 (2020).
Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568–571 (2014).
Chen, P. L. et al. Evaluation of immune signatures in longitudinal tumor samples yields perception into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. Most cancers Discov. 6, 827–837 (2016).
Wherry, E. J. et al. Molecular signature of CD8+ T cell exhaustion throughout continual viral an infection. Immunity 27, 670–684 (2007).
Hwang, S. S. et al. mRNA destabilization by BTG1 and BTG2 maintains T cell quiescence. Science 367, 1255–1260 (2020).
Lefebvre, C. et al. A human B-cell interactome identifies MYB and FOXM1 as grasp regulators of proliferation in germinal facilities. Mol. Syst. Biol. 6, 377 (2010).
Alvarez, M. J. et al. Purposeful characterization of somatic mutations in most cancers utilizing network-based inference of protein exercise. Nat. Genet. 48, 838–847 (2016).
Chen, J. et al. NR4A transcription components restrict CAR T cell operate in stable tumours. Nature 567, 530–534 (2019).
Lu, X. et al. Efficient combinatorial immunotherapy for castration-resistant prostate most cancers. Nature 543, 728–732 (2017).
Northrop, J. Ok., Thomas, R. M., Wells, A. D. & Shen, H. Epigenetic transforming of the IL-2 and IFN-γ loci in reminiscence CD8 T cells is influenced by CD4 T cells. J. Immunol. 177, 1062–1069 (2006).
Zediak, V. P., Johnnidis, J. B., Wherry, E. J. & Berger, S. L. Leading edge: persistently open chromatin at effector gene loci in resting reminiscence CD8+ T cells impartial of transcriptional standing. J. Immunol. 186, 2705–2709 (2011).
Kersh, E. N. et al. Speedy demethylation of the IFN-γ gene happens in reminiscence however not naive CD8 T cells. J. Immunol. 176, 4083–4093 (2006).
Pauken, Ok. E. et al. Epigenetic stability of exhausted T cells limits sturdiness of reinvigoration by PD-1 blockade. Science 354, 1160–1165 (2016).
Fornes, O. et al. JASPAR 2020: replace of the open-access database of transcription issue binding profiles. Nucleic Acids Res. 48, D87–D92 (2020).
Nussing, S. et al. Environment friendly CRISPR/Cas9 gene modifying in uncultured naive mouse T cells for in vivo research. J. Immunol. 204, 2308–2315 (2020).
Wherry, E. J., Blattman, J. N., Murali-Krishna, Ok., van der Most, R. & Ahmed, R. Viral persistence alters CD8 T-cell immunodominance and tissue distribution and leads to distinct phases of useful impairment. J. Virol. 77, 4911–4927 (2003).
Ahmed, R., Salmi, A., Butler, L. D., Chiller, J. M. & Oldstone, M. B. Number of genetic variants of lymphocytic choriomeningitis virus in spleens of persistently contaminated mice. Function in suppression of cytotoxic T lymphocyte response and viral persistence. J. Exp. Med. 160, 521–540 (1984).
Quigley, D. A. et al. Genomic hallmarks and structural variation in metastatic prostate most cancers. Cell 174, 758–769.e759 (2018).
Van Allen, E. M. et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350, 207–211 (2015).
Hugo, W. et al. Genomic and transcriptomic options of response to anti-PD-1 remedy in metastatic melanoma. Cell 168, 542 (2016).
Bebo, B. F., Schuster, J. C., Vandenbark, A. A. & Offner, H. Androgens alter the cytokine profile and scale back encephalitogenicity of myelin-reactive T cells. J. Immunol. 162, 35–40 (1999).
Gubbels Bupp, M. R., Potluri, T., Fink, A. L. & Klein, S. L. The confluence of intercourse hormones and getting older on immunity. Entrance. Immunol. 9, 1269 (2018).
Lin, A. A., Wojciechowski, S. E. & Hildeman, D. A. Androgens suppress antigen-specific T cell responses and IFN-γ manufacturing throughout intracranial LCMV an infection. J. Neuroimmunol. 226, 8–19 (2010).
Ashley, D. J. The 2 “hit” and a number of “hit” theories of carcinogenesis. Br. J. Most cancers 23, 313–328 (1969).
Cartwright, R. A., Gurney, Ok. A. & Moorman, A. V. Intercourse ratios and the dangers of haematological malignancies. Br. J. Haematol. 118, 1071–1077 (2002).
Fish, E. N. The X-files in immunity: sex-based variations predispose immune responses. Nat. Rev. Immunol. 8, 737–744 (2008).
Prepare dinner, M. B., Chow, W. H. & Devesa, S. S. Oesophageal most cancers incidence in the US by race, intercourse, and histologic sort, 1977–2005. Br. J. Most cancers 101, 855–859 (2009).
Edgren, G., Liang, L., Adami, H. O. & Chang, E. T. Enigmatic intercourse disparities in most cancers incidence. Eur. J. Epidemiol. 27, 187–196 (2012).
Klein, S. L. & Flanagan, Ok. L. Intercourse variations in immune responses. Nat. Rev. Immunol. 16, 626–638 (2016).
Montgomery, R. B. et al. Upkeep of intratumoral androgens in metastatic prostate most cancers: a mechanism for castration-resistant tumor progress. Most cancers Res. 68, 4447–4454 (2008).
Pernigoni, N. et al. Commensal micro organism promote endocrine resistance in prostate most cancers by means of androgen biosynthesis. Science 374, 216–224 (2021).
Edwards, A., Hammond, H. A., Jin, L., Caskey, C. T. & Chakraborty, R. Genetic variation at 5 trimeric and tetrameric tandem repeat loci in 4 human inhabitants teams. Genomics 12, 241–253 (1992).
Kazemi-Esfarjani, P., Trifiro, M. A. & Pinsky, L. Proof for a repressive operate of the lengthy polyglutamine tract within the human androgen receptor: attainable pathogenetic relevance for the (CAG)n-expanded neuronopathies. Hum. Mol. Genet. 4, 523–527 (1995).
Rayford, W. et al. Comparative evaluation of 1152 African-American and European-American males with prostate most cancers identifies distinct genomic and immunological variations. Commun. Biol. 4, 670 (2021).
Higano, C. S. et al. Actual-world outcomes of sipuleucel-T remedy in PROCEED, a potential registry of males with metastatic castration-resistant prostate. most cancers. Most cancers 125, 4172–4180 (2019).
He, M. X. et al. Transcriptional mediators of remedy resistance in deadly prostate most cancers. Nat. Med. 27, 426–433 (2021).
Bishop, J. L. et al. PD-L1 is very expressed in Enzalutamide resistant prostate most cancers. Oncotarget 6, 234–242 (2015).
Aggarwal, R. et al. Scientific and genomic characterization of treatment-emergent small-cell neuroendocrine prostate most cancers: a multi-institutional potential research. J. Clin. Oncol. 36, 2492–2503 (2018).
Moran, A. E., Polesso, F. & Weinberg, A. D. Immunotherapy expands and maintains the operate of high-affinity tumor-infiltrating CD8 T cells in situ. J. Immunol. 197, 2509–2521 (2016).
Polesso, F., Sarker, M., Weinberg, A. D., Murray, S. E. & Moran, A. E. OX40 agonist tumor immunotherapy doesn’t influence regulatory T cell suppressive operate. J. Immunol. 203, 2011–2019 (2019).
Polesso, F., Weinberg, A. D. & Moran, A. E. Late-stage tumor regression after PD-L1 blockade plus a concurrent OX40 agonist. Most cancers Immunol. Res. 7, 269–281 (2019).
Schofield, D. J. et al. Exercise of murine surrogate antibodies for durvalumab and tremelimumab missing effector operate and the flexibility to deplete regulatory T cells in mouse fashions of most cancers. mAbs 13, 1857100 (2021).
Polesso, F. et al. PD-1-specific “blocking” antibodies that deplete PD-1+ T cells current an inconvenient variable in preclinical immunotherapy experiments. Eur. J. Immunol. 51, 1473–1481 (2021).
Valkenburg, Ok. C., Amend, S. R. & Pienta, Ok. J. Murine prostate micro-dissection and surgical castration. J. Vis. Exp. https://doi.org/10.3791/53984 (2016).
Pavese, J., Ogden, I. M. & Bergan, R. C. An orthotopic murine mannequin of human prostate most cancers metastasis. J. Vis. Exp. https://doi.org/10.3791/50873 (2013).
Moran, A. E. et al. T cell receptor sign energy in Treg and iNKT cell growth demonstrated by a novel fluorescent reporter mouse. J. Exp. Med. 208, 1279–1289 (2011).
Murray, S. E. et al. Fibroblast-adapted human CMV vaccines elicit predominantly typical CD8 T cell responses in people. J. Exp. Med. 214, 1889–1899 (2017).
Gruner, B. M. et al. An in vivo multiplexed small-molecule screening platform. Nat. Strategies 13, 883–889 (2016).
Satija, R., Farrell, J. A., Gennert, D., Schier, A. F. & Regev, A. Spatial reconstruction of single-cell gene expression information. Nat. Biotechnol. 33, 495–502 (2015).
Wu, D. & Smyth, G. Ok. Digicam: a aggressive gene set check accounting for inter-gene correlation. Nucleic Acids Res. 40, e133 (2012).
Robertson, A. G. et al. Integrative evaluation identifies 4 molecular and medical subsets in uveal melanoma. Most cancers Cell 32, 204–220.e215 (2017).
Subramanian, A. et al. Gene set enrichment evaluation: a knowledge-based strategy for deciphering genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545–15550 (2005).
Li, B. & Dewey, C. N. RSEM: correct transcript quantification from RNA-seq information with or with out a reference genome. BMC Bioinf. 12, 323 (2011).
Ellrott, Ok. et al. Scalable open science strategy for mutation calling of tumor exomes utilizing a number of genomic pipelines. Cell Syst. 6, 271–281.e277 (2018).